title: Rebuttal from Dr Rho et al.
authors.forename: Jason
authors.initials: J
authors.lastname: Rho
authors.forename: Nancy
authors.initials: N
authors.lastname: Ho
authors.forename: Vinay
authors.initials: V
authors.lastname: Prasad
mesh_terms: D000420:Albuterol / Q000031:analogs & derivatives*; D000631:Aminopyridines / Q000008:administration & dosage* / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage* / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D058988:Phosphodiesterase 4 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012602:Scopolamine Derivatives / Q000627:therapeutic use*
chemical_list: D000631:Aminopyridines; D000893:Anti-Inflammatory Agents; D001549:Benzamides; D001993:Bronchodilator Agents; D058988:Phosphodiesterase 4 Inhibitors; D010726:Phosphodiesterase Inhibitors; D012602:Scopolamine Derivatives; D000420:Albuterol